Cargando…

IgA Plasma Cell Leukemia

Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Tejinder, Premalata, CS, Sajeevan, KV, Jain, Ankit, Batra, Ullas, Saini, KS, Satheesh, CT, Babu, K Govind, Lokanatha, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3167960/
https://www.ncbi.nlm.nih.gov/pubmed/21938244
http://dx.doi.org/10.4103/0974-2727.44415
Descripción
Sumario:Plasma cell leukemia (PCL) is a rare entity. There are two presentations of PCL, primary or secondary. The primary or de novo form of PCL presents with an acute and rapidly progressive leukemic phase. This form occurs when the patient has no pre-existing multiple myeloma (MM). The secondary form is the most advanced form of MM. The PCL is a rare disorder representing 1–2% of the diagnosed cases of MM. Median age at presentation is usually above 50 years. The monoclonal protein in patients with PCL may be IgG (50%), IgA (15%), or in rare cases IgD or IgE (6%). We report a case of IgA primary PCL that is very rare. Patient was started on combination therapy with vincristine, adriamycin, and dexamethasone. There was poor response and patient died three months after diagnosis.